Kuros Biosciences (CHIX:KURNZ) Beneish M-Score: -1.68 (As of Jun. 27, 2026)


CHIX:KURNZ Kuros Biosciences Ltd CHIX:KURNZ
70 GF Score
Price CHF18.29
GF Value CHF38.68
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Kuros Biosciences Beneish M-Score?

Kuros Biosciences CHIX:KURNZ +0.11% 70 Beneish M-Score is -1.68 as of Jun. 27, 2026. GuruFocus rates CHIX:KURNZ with a GF Score™ of 70/100 and a GF Value™ of CHF38.68 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 86.03% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.68 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Kuros Biosciences's Beneish M-Score or its related term are showing as below:

CHIX:KURNz' s Beneish M-Score Range Over the Past 10 Years
Min: -15.7   Med: -1.94   Max: 297.51
Current: -1.68

During the past 13 years, the highest Beneish M-Score of Kuros Biosciences was 297.51. The lowest was -15.70. And the median was -1.94.


Kuros Biosciences Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Kuros Biosciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kuros Biosciences Beneish M-Score Chart

Kuros Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.49 -2.27 -1.72 -1.98 -1.68

Kuros Biosciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.72 0.00 -1.98 0.00 -1.68

CHIX:KURNZ vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Kuros Biosciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kuros Biosciences Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's Beneish M-Score falls into.


CHIX:KURNZ
70GF Score
Kuros Biosciences Ltd CHIX:KURNZ
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kuros Biosciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Kuros Biosciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2589+0.528 * 0.9267+0.404 * 0.7993+0.892 * 1.7151+0.115 * 1.1285
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0235+4.679 * 0.022454-0.327 * 1.2217
=-1.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was CHF35.4 Mil.
Revenue was CHF146.1 Mil.
Gross Profit was CHF129.4 Mil.
Total Current Assets was CHF82.7 Mil.
Total Assets was CHF133.9 Mil.
Property, Plant and Equipment(Net PPE) was CHF4.7 Mil.
Depreciation, Depletion and Amortization(DDA) was CHF3.4 Mil.
Selling, General, & Admin. Expense(SGA) was CHF81.6 Mil.
Total Current Liabilities was CHF42.1 Mil.
Long-Term Debt & Capital Lease Obligation was CHF0.7 Mil.
Net Income was CHF2.6 Mil.
Gross Profit was CHF0.0 Mil.
Cash Flow from Operations was CHF-0.5 Mil.
Total Receivables was CHF16.4 Mil.
Revenue was CHF85.2 Mil.
Gross Profit was CHF69.9 Mil.
Total Current Assets was CHF49.1 Mil.
Total Assets was CHF92.7 Mil.
Property, Plant and Equipment(Net PPE) was CHF3.3 Mil.
Depreciation, Depletion and Amortization(DDA) was CHF3.0 Mil.
Selling, General, & Admin. Expense(SGA) was CHF46.5 Mil.
Total Current Liabilities was CHF22.9 Mil.
Long-Term Debt & Capital Lease Obligation was CHF1.4 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(35.353 / 146.058) / (16.374 / 85.159)
=0.242048 / 0.192276
=1.2589

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(69.916 / 85.159) / (129.402 / 146.058)
=0.821005 / 0.885963
=0.9267

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (82.666 + 4.679) / 133.875) / (1 - (49.076 + 3.315) / 92.702)
=0.347563 / 0.434845
=0.7993

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=146.058 / 85.159
=1.7151

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.971 / (2.971 + 3.315)) / (3.372 / (3.372 + 4.679))
=0.472638 / 0.41883
=1.1285

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(81.629 / 146.058) / (46.502 / 85.159)
=0.558881 / 0.546061
=1.0235

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.737 + 42.142) / 133.875) / ((1.386 + 22.918) / 92.702)
=0.320291 / 0.262173
=1.2217

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2.551 - 0 - -0.455) / 133.875
=0.022454

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Kuros Biosciences has a M-score of -1.68 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.68 mean?
Kuros Biosciences (CHIX:KURNZ) has a Beneish M-Score of -1.68 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Kuros Biosciences and its competitors. According to the industry distribution chart, Kuros Biosciences ranks #659 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 86%.
Is Kuros Biosciences' Beneish M-Score too high?
Kuros Biosciences' current Beneish M-Score is -1.68. Based on the distribution chart, Kuros Biosciences ranks #659 out of 766 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kuros Biosciences has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #659 out of 766 companies for Beneish M-Score. This places Kuros Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Kuros Biosciences and its competitors. Kuros Biosciences's current Beneish M-Score is -1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CHIX:KURNZ) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF38.68, compared to a current price of CHF18.29 — trading 52.7% below its estimated fair value. The current Beneish M-Score is -1.68. Kuros Biosciences' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Kuros Biosciences (CHIX:KURNZ), the current Beneish M-Score is -1.68 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuros Biosciences (CHIX:KURNZ) Overvalued in 2026?

Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued. The current stock price of CHF18.29 is trading 52.7% below its estimated GF Value™ of CHF38.68. GuruFocus considers Kuros Biosciences to be Significantly Undervalued.

Key valuation signals for CHIX:KURNZ:

  • Beneish M-Score: -1.68
  • GF Value™: CHF38.68 vs. price of CHF18.29 (52.7% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the CHIX:KURNZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kuros Biosciences Business Description

Address Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
70GF Score

Get the complete analysis for CHIX:KURNZ

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF18.29
Price
CHF38.68
GF Value